NDAORALTABLETPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
XPOVIO (selinexor) by Mthera Pharma is nuclear export inhibitors [moa]. First approved in 2019.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XPOVIO (selinexor) is an oral nuclear export inhibitor approved in 2019 for hematologic malignancies. It works by blocking XPO1-mediated nuclear export, causing accumulation of tumor suppressors in the nucleus and inducing apoptosis in cancer cells. The drug represents a novel mechanism-of-action class with potential across multiple cancer indications.
$0.086BPart D
Peak9.1 years to LOEProduct is at peak lifecycle stage with $86M in Part D spending and modest claim volume, indicating stable but limited adoption in a niche oncology market.
Mechanism of Action
Nuclear Export Inhibitors
Pharmacologic Class:
Nuclear Export Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started Jul 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Started May 2026
26 enrolled
MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Started Mar 2026
20 enrolled
Multiple Myeloma
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Started Nov 2025
228 enrolled
Relapsed or Refractory Multiple Myeloma
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
Started Nov 2024
39 enrolled
MDS
Worked on XPOVIO at Mthera Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.